Anti-human IL23A scFv Fragment (Risankizumab) (CAT#: TAB-620LC-S(P))

Recombinant monoclonal antibody Risankizumab is a humanized monoclonal antibody that specifically binds to human IL-23A and can be potentially used in the treatment of Crohn's disease, psoriasis, psoriatic arthritis and asthma.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Correlation of change from baseline to Week 12 in CDEIS score with [A] Log2-fold change [FC] from baseline in faecal calprotectin; and [B] Log2FC from baseline in faecal lactoferrin in the colon in the 600-mg risankizumab dose group. [C] Correlation of changes from baseline to Week 12 in faecal calprotectin levels with S-100A8 transcript expression in the colon in the 600-mg risankizumab dose group.

Figure 1 Correlation of change from baseline to Week 12 in CDEIS score with [A] Log2-fold change [FC] from baseline in faecal calprotectin; and [B] Log2FC from baseline in faecal lactoferrin in the colon in the 600-mg risankizumab dose group. [C] Correlation of changes from baseline to Week 12 in faecal calprotectin levels with S-100A8 transcript expression in the colon in the 600-mg risankizumab dose group.

Figure 2 [A] Differentially expressed miRNAs in colon biopsies 12 weeks after treatment with 600 mg risankizumab [Log2FC from baseline] versus baseline. Coloured dots represent each of the differentially expressed miRNAs. Levels of miR-223-3p in [B] colon and [C] faeces in patients receiving placebo and 600 mg risankizumab at baseline and Week 12. Whiskers represent the 10th and 90th percentiles of expression. Datasets for figures [B] and [C] were analysed for statistical significance using two-tailed unpaired Student's t-test; *p < 0.05. [D] Correlation of Log2FC in faecal calprotectin levels with Log2FC in miR-223-3p expression in colon biopsy tissue in the 600-mg risankizumab dose group. The red line represents the regression line of best fit [Pearson's correlation = 0.432] and the blue line represents a regression line of 1. Cpm, counts per million; FC, fold change; ns, not significant; RCC, reporter code count.

Figure 2 [A] Differentially expressed miRNAs in colon biopsies 12 weeks after treatment with 600 mg risankizumab [Log2FC from baseline] versus baseline. Coloured dots represent each of the differentially expressed miRNAs. Levels of miR-223-3p in [B] colon and [C] faeces in patients receiving placebo and 600 mg risankizumab at baseline and Week 12. Whiskers represent the 10th and 90th percentiles of expression. Datasets for figures [B] and [C] were analysed for statistical significance using two-tailed unpaired Student's t-test; *p < 0.05. [D] Correlation of Log2FC in faecal calprotectin levels with Log2FC in miR-223-3p expression in colon biopsy tissue in the 600-mg risankizumab dose group. The red line represents the regression line of best fit [Pearson's correlation = 0.432] and the blue line represents a regression line of 1. Cpm, counts per million; FC, fold change; ns, not significant; RCC, reporter code count.


Specifications

  • Host Species
  • Human
  • Derivation
  • Humanized
  • Type
  • Humanized antibody
  • Specificity
  • Human
  • Clone
  • Risankizumab
  • Applications
  • ELISA
  • Related Disease
  • Crohn's disease, psoriasis, psoriatic arthritis and asthma

Target

  • Alternative Names
  • IL23A; interleukin 23, alpha subunit p19; P19; SGRF; IL-23; IL-23A; IL23P19; interleukin-23 subunit alpha; IL-23-A; IL-23p19; IL-23 subunit alpha; interleukin 23 p19 subunit; interleukin-23 subunit p19; JKA3 induced upon T-cell activation; interleukin-six, G-CSF related factor

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone Risankizumab"

See other products for "IL23A"

Single-domain Antibody

CAT Product Name Application Type
NAB-1953-VHH Recombinant Anti-human IL23A VHH Single Domain Antibody WB, IP, ICC, FC, FA Llama VHH
TAB-005LC-VHH Anti-human IL23A Recombinant Antibody (119A3) (TAB-005LC-VHH) ELISA Single domain antibody

Chimeric Antibody

CAT Product Name Application Type
TAB-607LC Anti-human IL23A Recombinant Antibody (E11E7Chimera) (TAB-607LC) ELISA, Neut, FuncS Chimeric antibody (rat/human)
TAB-607LC-S(P) Anti-human IL23A scFv Fragment (E11E7Chimera) ELISA Chimeric antibody (rat/human)
TAB-607LC-F(E) Anti-human IL23A Fab Fragment (E11E7Chimera) ELISA Chimeric antibody (rat/human)

Humanized Antibody

CAT Product Name Application Type
TAB-616LC Anti-human IL23A Recombinant Antibody (A3M0) (TAB-616LC) ELISA, FC, Inhib, FuncS Humanized antibody
TAB-617LC Anti-human IL23A Recombinant Antibody (A3M1) (TAB-617LC) ELISA, FC, Inhib Humanized antibody
TAB-618LC Anti-human IL23A Recombinant Antibody (A3N1) (TAB-618LC) ELISA, FC, Inhib Humanized antibody
TAB-605LC-S(P) Anti-human IL23A scFv Fragment (FM303) ELISA Humanized antibody
TAB-608LC-S(P) Anti-human IL23A scFv Fragment (21-4) ELISA Humanized antibody

Rabbit Monoclonal Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-875 Afuco™ Anti-IL23A ADCC Recombinant Antibody (Tildrakizumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody
AFC-TAB-620LC Afuco™ Anti-IL23A ADCC Recombinant Antibody (Risankizumab), ADCC Enhanced ELISA ADCC enhanced antibody
AFC-TAB-008ML Afuco™ Anti-IL23A ADCC Recombinant Antibody (Brazikumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, Inhib ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-620LC-S(P). Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare